Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171896 | 1.00 | CHRNB2 (0.68) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| Ammonia Solution, Strong SCHEMBL7207615 | 0.98 | CHRNB2 (0.66) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL422229 | 0.90 | CYP2C9 (0.70) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL23596366 | 0.89 | CHRNB2 (0.60) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL20730105 | 0.89 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL19055583 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL9367178 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL4888697 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL30542607 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL3229561 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP3A4CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, CERS2 | CHRNB2 3669/4885CHRNA4 4317/4885CYP3A4 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.